A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin.

Trial Profile

A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Dulaglutide (Primary) ; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARD-5
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2017 Results of a post-hoc pooled analysis of AWARD -1,-2, -3, -5 and -6 studies evaluating the magnitude of the lipid changes in patients with type 2 diabetes receiving once-weekly dulaglutide 1.5 mg, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results of a post-hoc analysis from AWARD -2, -4, and -5 studies evaluating the effect of dulaglutide on A1c in type 2 diabetes patients positive or negative for GAD antibodies, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top